Navigation Links
GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
Date:1/13/2009

TORONTO, Jan. 13 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced it has been granted U.S. Patent # 7,473,528 entitled "Method for the detection of Chagas disease related gene transcripts in blood". This patent protects the Company's discovery of a blood biomarker-based method of testing for Chagas disease, a serious and potentially fatal disease resulting from parasitic infection. Chagas disease is a significant public health issue affecting more than 11 million people worldwide each year.

"The Sentinel Principle(TM) technology is the basis of not only this issued patent but also for the personalized health management system we are developing which applies genomic information to monitor and address health concerns on an individualized basis," stated Dr. Choong-Chin Liew, the discoverer of the Sentinel Principle and Co-founder, Chief Scientist and Director of GeneNews. "GeneNews has a broad array of pending patent applications in diverse disease areas including oncology, cardiovascular, neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This is our first patent issuance based on our Sentinel Principle platform technology and represents an important initial milestone to realize commercial value from our pipeline of discoveries." The Company currently has five issued patents and more than 70 pending patent applications, the majority of which are based on the application of the Sentinel Principle.

    About GeneNews
    ---------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. GeneNews announces management changes to support commercialization of ColonSentry(TM)
11. GeneNews launches worlds first blood test for colorectal cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... LONDON , Feb. 7, 2017 Report ... $12.5 billion by 2021 from $8.3 billion in 2016 ... from 2016 to 2021. Report Includes - An ... of global market trends, with data from 2015 and ... through 2021. - Segmentation of the market on the ...
Breaking Biology News(10 mins):